Barry Byrne
Pediatric Cardiology · Gainesville, FLNPI 1578507398
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $228,004 of the $288,626 with a category attached, or 79.0%. 16 manufacturers reported payments, led by Pfizer at 38.4% of the total. Reporting peaked in 2019 at $82,715 and has fallen 90.0% since, to $8,231 in 2025. Among pediatric cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $1749.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$111K
- Sarepta Therapeutics, Inc.$47K
- Sanofi$33K
- AstraZeneca$28K
- Amicus Therapeutics, Inc.$26K
- Vertex$15K
- plus $28K from 10 others
Across 397 payments — averaging $10,806 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sarepta Therapeutics, Inc.$2M
- Amicus Therapeutics, Inc.$1M
- Roche Products Limited$508K
- Pfizer$274K
- Hoffmann-la Roche Limited$213K
- Sanofi US Services Inc.$128K
- plus $184K from 4 others
What the payments were for
- Consulting fees$228,00479%
- Speaking & faculty fees$11,1784%
- Travel & lodging$44,69115%
- Food & beverage$4,6732%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 33 | $110,761 |
| Sarepta Therapeutics, Inc. | 29 | $47,262 |
| Sanofi | 31 | $32,653 |
| AstraZeneca | 9 | $28,370 |
| Amicus Therapeutics, Inc. | 23 | $26,114 |
| Vertex | 2 | $15,033 |
| PTC Therapeutics, Inc. | 8 | $11,812 |
| Eli Lilly | 9 | $7,009 |
| F. Hoffmann-la Roche AG | 6 | $3,542 |
| Regeneron | 5 | $2,782 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 3 | $2,640 |
| Biomarin Pharmaceutical Inc. | 1 | $272 |
| UCB, Inc. | 2 | $160 |
| Insmed, Inc. | 1 | $116 |
| ITF Therapeutics LLC | 1 | $64 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIZYME$28,469
- Exondys 51$17,678
- POMBILITI$9,324
- OPFOLDA$9,324
- Elevidys$6,076
- ZOLGENSMA$2,560
- GALAFOLD$1,692
- Non-Covered Product$1,637
- NEXVIAZYME$750
- NO PRODUCT DISCUSSED$704
How this compares
$288,626 in reported general payments places this provider in the 95th percentile of 185 pediatric cardiology providers in Florida.
Other pediatric cardiology in Gainesville
- Mohammad Al MousilyGainesville$14K
- Philip ChangGainesville$3K
- Dipankar GuptaGainesville$3K
- Renata ShihGainesville$2K
- Joseph StidhamGainesville$2K
- Frederick FrickerGainesville$2K
- Aurelio ReyesApopka$347K
- Shyam SathanandamMiami$252K
- Jeremy RingewaldTampa$139K
- David NykanenOrlando$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.